|
Company:
|
BEIGENE, LTD. (BGNE)
|
|
Form Type:
|
4
|
|
Filing Date:
|
3/20/2017
|
|
CIK:
|
0001651308
|
|
Address:
|
C/O MOURANT OZANNES CORPORATE SERVICES
94 SOLARIS AVENUE, CAMANA BAY
|
|
City, State, Zip:
|
GRAND CAYMAN, KY1-1108
|
|
Telephone:
|
13459494123
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$78.96
|
Change:
1.36 (1.75%)
|
Trade Time:
02:14 PM EST
|
Market Cap:
$40.97B
|
|
|
|
|
|
|
Description of Business
|
|
We are a globally focused, clinical-stage biopharmaceutical company
dedicated to becoming a leader in the discovery and development of innovative,
molecularly targeted and immuno-oncology drugs for the treatment of cancer. We
believe the next generation of cancer treatment will utilize therapeutics both
as monotherapies and in combination to attack multiple underlying mechanisms of
cancer cell growth and survival. We further believe that discovery of
next-generation cancer therapies requires new research tools. To that end, we
have developed a proprietary cancer biology platform that addresses the
importance of tumor-immune system interactions and the value of primary biopsies
in developing new models to support our drug discovery effort.
Our strategy is to develop a pipeline of drug candidates with the potential
to be best-in-class monotherapies and also important components of
multiple-agent combination regimens.
|
|
|
|